SEC Form 4 · accession 0001209191-18-044758
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jill Marie Broadfoot
Officer — Chief Financial Officer
Period of report
Jul 30, 2018
Accepted (ET)
Aug 1, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.8151 | Jul 30, 2018 | A | 200,000 | A | — | Jul 30, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F11/4 of the shares subject to this option shall vest and become exercisable on July 30, 2018, and the remainder shall thereafter vest and become exercisable in 36 equal monthly installments, such that this option will be fully exercisable on July 30, 2022. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.